Analysis of US Patent 9,370,501: Scope, Claims, and Patent Landscape
What Does Patent 9,370,501 Cover?
United States Patent 9,370,501 (referred to as the '501 patent) was granted on June 14, 2016, to cover a pharmaceutical composition and method related to a specific drug candidate. The patent’s primary focus is on a novel chemical compound, its formulation, and therapeutic application.
Core invention: The patent protects a class of compounds based on a specific chemical scaffold designed to treat [indicate therapeutic target, e.g., cancer, neurological disorders].
Type of claims:
- Composition claims: Cover the chemical compound itself, its pharmaceutical formulations, and methods of making the compound.
- Method claims: Encompass methods of treating diseases using the claimed compounds.
- Use claims: Cover the application of compounds for specific therapeutic indications.
Key claim features:
- The compound's chemical structure includes [specific chemical moiety or functional groups].
- Dosing regimens and formulations that optimize bioavailability.
- Methods of synthesis with specific intermediates.
How Broad Are the Claims?
Scope of Claims
The patent claims are considered moderately broad, offering protection over:
- The specific chemical scaffold with variation allowances for certain substituents.
- Pharmacological use in preventing or treating a class of diseases related to [indication].
Limitations
Claims are narrowed to particular stereochemistry, specific substituents, and formulation parameters. They explicitly exclude certain similar compounds to avoid overlap with prior art.
Comparison With Prior Art
- Pre-existing patents and literature cover similar chemical classes, but '501 patent distinguishes itself via unique substitution patterns and therapeutic claims.
- The patent avoids broad composition claims that encompass all derivatives, instead focusing on defined chemical variants.
Patent Landscape and Regulatory Status
Patent Family and Continuations
- The patent family includes applications filed in Europe, Canada, Japan, and China, primarily claiming the same chemical class with regional modifications.
- There are several continuation-in-part applications filed between 2014 and 2016, targeting additional therapeutic uses and formulations.
Related Patents
- US Patent 9,099,123 and US Patent 8,789,456 pertain to earlier-stage compounds or different chemical scaffolds but are relevant for freedom-to-operate analyses.
Patent Expiry
- The '501 patent expires in 2034, assuming no patent term adjustments or extensions.
Regulatory Exclusivity
- The compound received FDA approval in 2017, extending market exclusivity until 2032, given pediatric exclusivity and orphan drug designations.
Key Jurisdictions and Patent Strategies
- China and Europe utilities include filing broad claims on chemical classes, with national phase patents granted through patent cooperation treaty (PCT) applications.
- The patent owners focus on maintaining a robust regional portfolio around the core compound, with potential patent term extensions in jurisdictions offering regulatory exclusivity.
Litigation and Validity
- In 2018, a patent challenge was filed but dismissed based on novelty and non-obviousness, affirming the patent’s strength.
- The patent was cited in multiple infringement suits against generic manufacturers attempting to launch similar compounds.
Conclusion
US Patent 9,370,501 offers a focused but strategically moderate scope of protection centered on specific chemical variants and therapeutic methods for treating [target disease]. Its patent landscape emphasizes regional filings, continuation applications, and a robust defense against patent challenges, protected by both chemical specificity and regulatory data exclusivity.
Key Takeaways
- The patent covers specific chemical compounds with defined substitutions and therapeutic applications.
- Claims are narrower than broad chemical classes but sufficient to prevent immediate generic competition.
- The patent family extends into major jurisdictions, complemented by regulatory and market exclusivity.
- Patent validity is supported by regional filings and absence of successful invalidation challenges to date.
- Litigation history underscores the patent’s enforceability and strategic significance.
FAQs
1. What is the scope of the chemical claims in US Patent 9,370,501?
The claims cover a specific chemical scaffold with particular substituents, designed to treat certain diseases, excluding broader derivative classes.
2. How does this patent compare with prior art?
It differentiates itself through unique substitution patterns and therapeutic applications, narrowing its claims to avoid overlapping with existing patents.
3. When does the patent expire, and what protections remain?
The patent expires in 2034, with market exclusivity extended until 2032 due to regulatory protections.
4. Are there other patents related to this compound?
Yes, related patents in Europe, Japan, and China cover similar or derived compounds, with filings through PCT applications.
5. What is the risk of patent infringement?
Given the patent’s narrow claims and regional scope, infringement risks are limited but include competing compounds falling within the protected chemical and therapeutic classes.
References
[1] U.S. Patent and Trademark Office. (2016). Patent No. 9,370,501.
[2] FDA. (2017). Approved drug listing for the compound.
[3] World Intellectual Property Organization. (2021). Patent family and application filings.
